Literature DB >> 18078968

Inhibition of c-Jun N-terminal kinase sensitizes tumor cells to flavonoid-induced apoptosis through down-regulation of JunD.

Sung-Ho Kook1, Young-Ok Son, Yong-Suk Jang, Kyung-Yeol Lee, Seung-Ah Lee, Beom-Soo Kim, Hyun-Jeong Lee, Jeong-Chae Lee.   

Abstract

Reduction of susceptibility to apoptosis signals is a crucial step in carcinogenesis. Therefore, sensitization of tumor cells to apoptosis is a promising therapeutic strategy. c-Jun NH2-terminal kinase (JNK) has been implicated in stress-induced apoptosis. However, many studies also emphasize the role of JNK on cell survival, although its mechanisms are not completely understood. Previously, we found that inhibition of JNK activity promotes flavonoid-mediated apoptosis of human osteosarcoma cells. We thus determined whether inhibition of JNK sensitizes tumor cells to a bioflavonoid-induced apoptosis, and whether this effect of JNK is a general effect. As the results, quercetin and genistein as well as a flavonoid fraction induced apoptosis of tumor cells, which was further accelerated by specific JNK inhibitor, SP600125 or by small interfering RNA specific to JNK1/2. This effect was specific to types of cells because it was further apparent in tumorigenic cell lines. Inhibition of JNK by SP600125 also reduced flavonoid-stimulated nuclear induction of JunD which was known to have protective role in apoptosis, whereas JNK inhibition alone had little effect on apoptosis. The flavonoid-induced apoptosis of tumor cells was significantly enhanced by transfecting them with antisense JunD oligonucleotides. These results suggest that inhibition of JNK facilitates flavonoid-induced apoptosis through down-regulation of JunD, which is further sensitive to tumor cells. Therefore, combination with a specific JNK inhibitor further enhances the anti-cancer and chemopreventive potential of bio-flavonoids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078968     DOI: 10.1016/j.taap.2007.11.004

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  COMP-Ang1 enhances DNA synthesis and cell cycle progression in human periodontal ligament cells via Tie2-mediated phosphorylation of PI3K/Akt and MAPKs.

Authors:  Shin-Saeng Lim; Sung-Ho Kook; Jeong-Chae Lee
Journal:  Mol Cell Biochem       Date:  2016-04-23       Impact factor: 3.396

2.  Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125.

Authors:  Sabrina Marozin; Jennifer Altomonte; Sibylle Apfel; Phat X Dinh; Enrico N De Toni; Antonia Rizzani; Andreas Nüssler; Nobuyuki Kato; Roland M Schmid; Asit K Pattnaik; Oliver Ebert
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  SPAG9 is overexpressed in osteosarcoma, and regulates cell proliferation and invasion through regulation of JunD.

Authors:  Chi Xiao; Lin Fu; Chongnan Yan; Fenyong Shou; Qi Liu; Lei Li; Shaoqian Cui; Jingzhu Duan; Guoxin Jin; Jianhua Chen; Yuanming Bian; Xu Wang; Huan Wang
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

4.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

5.  Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.

Authors:  Shigeo Ohba; Yuichi Hirose; Takeshi Kawase; Hirotoshi Sano
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

6.  Enhancing Radiotherapeutic Effect With Nanoparticle-Mediated Radiosensitizer Delivery Guided By Focused Gamma Rays In Lewis Lung Carcinoma-Bearing Mouse Brain Tumor Models.

Authors:  Sa-Hoe Lim; Chun-Hao Li; Young-Il Jeong; Woo-Youl Jang; Jin-Myung Choi; Shin Jung
Journal:  Int J Nanomedicine       Date:  2019-11-13

7.  MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD.

Authors:  Yi Zhang; Xiaoman Xu; Meng Zhang; Xin Wang; Xue Bai; Hui Li; Liang Kan; Yong Zhou; Huiyan Niu; Ping He
Journal:  BMC Cancer       Date:  2016-05-16       Impact factor: 4.430

8.  BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.

Authors:  Chisato Inoue; Sayaka Sobue; Yuka Aoyama; Naoki Mizutani; Yoshiyuki Kawamoto; Yuji Nishizawa; Masatoshi Ichihara; Akihiro Abe; Fumihiko Hayakawa; Motoshi Suzuki; Yoshinori Nozawa; Takashi Murate
Journal:  Biochem Biophys Rep       Date:  2018-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.